REVIEW article
Front. Cell. Infect. Microbiol.
Sec. Virus and Host
Combating Klebsiella pneumoniae: From Antimicrobial Resistance Mechanisms to Phage-Based Combination Therapies
Provisionally accepted
- 1Ningbo University, Ningbo, China
- 2The First People's Hospital of Yunnan Province, Kunming, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Klebsiella pneumoniae (K. pneumoniae) is a central pathogen in both nosocomial and community-acquired infections worldwide, capable of causing pneumonia, urinary tract infections (UTIs) and bacteremia. In recent years, the spread of multi-drug resistant (MDR) bacterial pathogens has become a major public health challenge. Traditional antibiotics, which are increasingly ineffective due to escalating resistance, significant adverse effects, and limited therapeutic efficacy, underscore the urgent need for novel strategies. The primary antimicrobial resistance mechanisms of K. pneumoniae currently include alterations of drug target sites, modified enzyme-mediated antibiotic inactivation, permeability barriers to antimicrobial agents, active efflux systems, synergistic resistance mechanisms involving biofilm-persisters-quorum sensing (QS) and heteroresistance. While phage therapy offers precise targeting of pathogenic bacteria, its standalone use is hampered by obstacles such as the rapid evolution of bacterial resistance and narrow host ranges. Accordingly, combinatorial phage therapy has emerged as a key research focus. In this review, we not only summarize the multidimensional antimicrobial resistance mechanisms of K. pneumoniae and the principles of synergistic phage strategies but also evaluate the potential for clinical translation and current challenges, providing a theoretical framework for the precise treatment of multidrug-resistant K. pneumoniae (MDRKP) infections, so as to promote the clinical application of phage-based combination therapy in the post-antibiotic era. Beyond summarizing recent advances, this work also provides a unique translational perspective by critically evaluating the synergy, clinical applicability, and challenges of combinatorial phage approaches—including phage-antibiotic, phage-AMP, and phage-nanocarrier therapies—against MDRKP, filling a critical gap in existing reviews.
Keywords: K.pneumoniae, Phage, Antimicrobial resistance mechanisms, phage-based combination therapy, clinical translation
Received: 23 Aug 2025; Accepted: 27 Oct 2025.
Copyright: © 2025 DING, Liao, Yan, Ma, Rui and Jiang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Zheng Rui, ynkmzheng@gmail.com
Liming Jiang, jiangliming@nbu.edu.cn
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.